Group 1 - The company plans to issue 30.4875 million subscription shares to Huayuan Management Consulting (Hong Kong) Limited at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% compared to the last trading price of HKD 1.93 per share [1] - The net proceeds from the subscription are approximately HKD 49.78 million, which will be used for general working capital and the Phase III clinical trial of KX-826 [1]

開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ ） 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 （股 份 代 號：9939） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 根據一般授權認購新股份 根據一般授權認購新股份 於2025年11月12日（交易時段後），本公司與認購人訂立該協議，據此，本公 司有條件同意配發及發行，認購人有條件同意以認購價每股1.64港元認購合 共30,487,500股股份。 認購人由中新蘇州工業園區創業投資有限公司全資擁有。本公司的現有股東 原點創業投資亦由中新蘇州工業園區創業投資有限公司全資擁有。認購事項 完成後，認購人及原點創業投資將合共持有49,115,740 股股份，相當於本公 司已發行股本的10.49%及擴大後股本的9.85%。 認購股份相當於(i)本公司於本公告日期的已發行股本約6.51% ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 開拓藥業有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09939 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 700,000,000 | USD | | 0.0001 | USD | | 70,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 700,000,000 | USD | | 0.0001 | USD | | 70,000 | FF301 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根 ...

本次交易涉及其他关联方：Tong Youzhi。 智通财经APP获悉，香港联交所最新资料显示，10月23日，KT International Investment Limited增持开拓 药业-B(09939)10万股，每股作价1.93港元，总金额为19.3万港元。增持后最新持股数目约为4890.027万 股，最新持股比例为10.44%。 ...

香港联交所最新资料显示，10月23日，KT International Investment Limited增持开拓药业-B(09939)10万 股，每股作价1.93港元，总金额为19.3万港元。增持后最新持股数目约为4890.027万股，最新持股比例 为10.44%。 本次交易涉及其他关联方：Tong Youzhi。 ...

Group 1 - KT International Investment Limited increased its stake in 开拓药业-B (09939) by 150,000 shares at a price of HKD 2.046 per share, totaling HKD 306,900 [1] - After the increase, KT International's total shareholding is approximately 48,800,270 shares, representing a stake of 10.42% [1]

智通财经APP获悉，香港联交所最新资料显示，10月22日，KT International Investment Limited增持开拓 药业-B(09939)15万股，每股作价2.046港元，总金额为30.69万港元。增持后最新持股数目约为4880.027 万股，最新持股比例为10.42%。 （原标题：KT International Investment Limited增持开拓药业-B(09939)15万股 每股作价2.046港元） ...

Group 1 - KT International Investment Limited increased its stake in Kintor Pharmaceutical Limited (09939) by purchasing 150,000 shares at a price of HKD 2.046 per share, totaling HKD 306,900 [1] - After the acquisition, KT International's total shareholding in Kintor Pharmaceutical is approximately 48,800,270 shares, representing a 10.42% ownership stake [1]

Core Insights - The stock of Innovent Biologics-B (09939) was transferred from Futu Securities International Hong Kong to Adept Securities Futures on October 15, with a market value of HKD 64.43 million, representing 6.49% of the total shares [1] Company Developments - Innovent Biologics-B has completed the enrollment of 130 participants in the long-term safety trial for its self-developed tyrosinase inhibitor KT-939, which effectively inhibits melanin production [1] - KT-939 precisely targets tyrosinase, efficiently blocking the oxidation process of tyrosine, thereby effectively curbing melanin production while also possessing antioxidant and anti-inflammatory properties [1] - The product demonstrates significant advantages in both efficacy and safety for cosmetic applications [1]

Core Viewpoint - The recent transfer of shares of 开拓药业-B (09939) indicates a strategic shift among shareholders, with a significant market value of HKD 64.43 million being moved, representing 6.49% of the total shares [1] Group 1: Shareholder Activity - On October 15, shareholders of 开拓药业-B transferred their shares from 富途证券国际香港 to 艾德证券期货, with a total market value of HKD 64.43 million [1] - This transfer accounts for 6.49% of the company's total shares, suggesting a notable shift in shareholder strategy [1] Group 2: Product Development - 开拓药业-B has completed the enrollment of 130 participants in the long-term safety trial for its self-developed tyrosinase inhibitor KT-939 [1] - KT-939 is designed to effectively inhibit melanin production by precisely targeting tyrosinase, blocking the oxidation process of tyrosine [1] - The product also boasts antioxidant and anti-inflammatory properties, providing significant advantages in both efficacy and safety for cosmetic applications [1]